Skip to main content
. 2023 Feb 23;41(13):2184–2197. doi: 10.1016/j.vaccine.2023.02.057

Fig. 1.

Fig. 1

AKS-452 Phase II clinical study design. Phase II was a 2 × 26 design; i.e., Cohort 1 was a single-dose (90 µg) and Cohort 2 was a two-dose (45 µg) regimen in which subjects were enrolled and dosed concurrently. The dosing regimens were based on safety and immunogenicity outcomes of the interim results of the phase I study [15].